Back to Search

An Open-Label, Multicenter, Phase I/II Trial Evaluating the Safety, Efficacy, and Pharmacokinetics of Escalating Doses of Mosunetuzumab (BTCT4465A) as a Single Agent and Combined With Atezolizumab in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia

  • Protocol Number: 201505024
  • Principal Investigator: Bartlett, Nancy
  • Cancer Types: Lymphoma

For more information on this trial, contact us here:


Brief Summary

Protocol Interventions